Status:
UNKNOWN
Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis
Lead Sponsor:
Sunshine Coast Hospital and Health Service
Collaborating Sponsors:
The Prince Charles Hospital
Mater
Conditions:
Bronchiectasis
Cystic Fibrosis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The goal of this clinical trial is to assess the feasibility of ceftolozane/tazobactam (C/T) administered on an outpatient parenteral antibiotic therapy programme to patients with a current infective ...
Detailed Description
For patients with cystic fibrosis (CF) and non-CF bronchiectasis, chronic airway infection with Gram-negative organisms such as Pseudomonas aeruginosa and Burkholderia cepacia complex species (BCC) is...
Eligibility Criteria
Inclusion
- Diagnosis of CF or non-CF bronchiectasis
- Colonised with P. aeruginosa or BCC species
- Current infectious exacerbation requiring treatment with intravenous antibiotics
- Productive of sputum
Exclusion
- Unable to consent
- Active pregnancy (as confirmed by urine beta-HCG)
- Not appropriate for OPAT (as determined by treating clinician)
- Estimated Creatinine Clearance \< 50 millilitres/min
- History of hypersensitivity reaction to piperacillin/tazobactam or members of the cephalosporin class of antibiotics
- Unable to expectorate
Key Trial Info
Start Date :
October 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06035055
Start Date
October 1 2023
End Date
January 1 2024
Last Update
September 13 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.